Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma

The use of bortezomib in treatment of multiple myeloma (MM) has become a backbone of many induction regimens. Its efficacy when given twice weekly is often at the expense of peripheral neuropathy (PN) despite of adopting subcutaneous (SQ) administration. In an attempt to reduce the impact on quality of life (QOL) without compromising response, studies using weekly bortezomib with cyclophosphamide and dexamethasone (VCD) or lenalidomide and dexamethasone (RVD-lite) in transplant ineligible patients have demonstrated to be effective treatment regimens.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Cesar Rodriguez, Jeffrey Lantz, Faisal Akbar, Lyndsey Lantz, Emily Dressler Source Type: research